Eli Lilly: Late-breaking Lebrikizumab Data Shows Long-lasting Results In Atopic Dermatitis
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said new detailed results from phase 3 monotherapy studies in atopic dermatitis showed investigational lebrikizumab provided robust and durable…
Eli Lilly: Late-breaking Lebrikizumab Data Shows Long-lasting Results In Atopic Dermatitis
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said new detailed results from phase 3 monotherapy studies in atopic dermatitis showed investigational lebrikizumab provided robust and durable…